Who mentions $HELP most on Surfaced?

@investmentguru_ (InvestmentGuru) mentions $HELP most — 2 mentions in the past 12 months.

When was $HELP first mentioned on Surfaced?

The earliest tracked mention of $HELP in the Surfaced archive was on Mar 31, 2026.

How many voices track $HELP?

2 FinTwit voices have mentioned $HELP 3 times in the past 12 months.

What kind of voices mention $HELP most?

$HELP is mentioned most by Long Research voices on Surfaced.

Last 12mo stats

mentions

voices

$HELP

Cybin Inc

$HELP

Cybin Inc

Past 12mo:3mentions2voices

All voices3 mentions since Mar 2026calls only

Loading price chart…

About this stock

$HELP (Cybin Inc) received 3 mentions from 2 distinct FinTwit voices over the past 12 months, with the first mention appearing on March 31, 2026. @investmentguru_ accounts for 2 mentions, making it the most-active voice discussing the stock, while @adamfeuerstein contributed 1 mention. The most recent discussion occurred on April 20, 2026, when @investmentguru_ included $HELP in a watchlist of psychedelic biotechs following a White House executive order on psychedelic medicine review. In that analysis, $HELP was categorized as a psilocybin play with Phase 3 trials for CYB003, UK approval for a second pivotal depression study, and $500M in secured financing.

AI-generated from tracked posts · updated Jul 21, 2026

Frequently asked

Related stocks

$ALKSAlkermes

$ALMSAlumis

$ASNDAscendis Pharma A/S

$ATAIATAI Life Sciences

Recent mentions

3 mentions

@investmentguru_Apr 20, 2026 · 11:03 AM

Play to watch today $PBM $ATAI $CMPS $HELP $MNMD $GHRS

Open on X

@investmentguru_Apr 20, 2026 · 11:02 AM

The White House Just Opened the Door to Psychedelic Medicine On April 18, Trump signed an EO fast-tracking federal review of psychedelic drugs — with ibogaine front and center. Joe Rogan was literally in the Oval Office. Here’s what the order means: → $50M in federal research funding committed → FDA to fast-track psilocybin & ibogaine review → Right to Try pathway opened for desperately ill patients → DEA restrictions on clinical trials being reduced → 3 psychedelics added to FDA National Priority Voucher program $PBM (Psyence Biomedical) was the top gainer — up 200%+ — as a clinical-stage ibogaine & psilocybin company with GMP manufacturing infrastructure already in place. But the trade doesn’t stop there. Here’s the full watchlist 👇 Watchlist — Tiered by Relevance: 🥇 Most Direct Ibogaine Exposure $PBM — GMP ibogaine manufacturer, Phase IIb psilocybin trials, small float (already moved hard) $ATAI — owns DemeRx (Phase 1 ibogaine data), Peter Thiel backed, largest pure-play psychedelic biotech. Most direct public ibogaine play in the market. 🥈 Psilocybin / Broader Psychedelic Plays (sentiment lift) $CMPS (Compass Pathways) — Phase 3 trials for COMP360 in treatment-resistant depression, positive results already reported from first study $HELP (Cybin) — Phase 3 trials for CYB003, UK approval for second pivotal depression study, $500M financing secured $MNMD (MindMed) — LSD & ibogaine derivatives pipeline, pivotal Phase 3 data expected in 2026 $GHRS (GH Research) — fast-acting inhaled psychedelic compound, shares more than doubled YTD The real catalyst is VA or DoD funding announcements — not the EO itself. The EO just funds the work to study it. Ibogaine also carries cardiac safety risks (QT prolongation) that make the clinical path harder than psilocybin. These are high-risk, pre-revenue biotechs. Most are pre-profitability. Position size accordingly. Not financial advice. DYOR.

Open on X

@adamfeuersteinMar 31, 2026 · 1:20 PM

Let's not do more sketchy YouTube stock promotion, psychedelics! A great story about $HELP $ATAI from @elaineywchen Link below. The psychedelics field is at a pivotal moment. Having combatted years of skepticism and stigma, several psychedelic-focused biotechs are now reaching late-stage development and trying to gain a foothold in the broader biopharma industry. That's why it caught STAT's attention earlier this year when we saw a handful of YouTube accounts had uploaded videos making exaggerated claims about psychedelic drug candidates being developed by Helus Pharma and AtaiBeckley. The videos said they were paid for by third-party marketing agencies on behalf of the biotechs. When reached for comment, both companies distanced themselves from the videos. But observers in the field said that, regardless of how aware drugmakers may or may not have been about the promotional strategies, such videos threaten to undermine efforts by the psychedelics field to establish credibility with the public and regulators. Read the story here: https://t.co/RAZwtwq6GH

Open on X